Oramed Pharmaceuticals (XTAE:ORMP) Cyclically Adjusted Book per Share: ₪9.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:ORMP Oramed Pharmaceuticals Inc XTAE:ORMP
23 GF Score
Price ₪12.72
! 4 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals Cyclically Adjusted Book per Share?

Oramed Pharmaceuticals XTAE:ORMP -5.78% 23 Cyclically Adjusted Book per Share is ₪9.74 as of Mar. 2026. GuruFocus rates XTAE:ORMP with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was ₪17.720. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₪9.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Oramed Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 10.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 16.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Oramed Pharmaceuticals was 21.50% per year. The lowest was 8.30% per year. And the median was 15.40% per year.

As of today (2026-08-03), Oramed Pharmaceuticals's current stock price is ₪12.72. Oramed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ₪9.74. Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 1.31.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oramed Pharmaceuticals was 16.95. The lowest was 0.70. And the median was 2.61.


Oramed Pharmaceuticals  (XTAE:ORMP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=12.72/9.74
=1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oramed Pharmaceuticals was 16.95. The lowest was 0.70. And the median was 2.61.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Oramed Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Oramed Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Cyclically Adjusted Book per Share Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.44 7.29 9.30 9.84 9.59

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.53 9.31 9.66 9.59 9.74

XTAE:ORMP vs CAMP, PYXS, ALEC: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


XTAE:ORMP
23GF Score
Oramed Pharmaceuticals Inc XTAE:ORMP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oramed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=17.72/330.2130*330.2130
=17.720

Current CPI (Mar. 2026) = 330.2130.

Oramed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201605 7.182 240.229 9.872
201608 6.047 240.849 8.291
201611 5.502 241.353 7.528
201702 4.882 243.603 6.618
201705 4.527 244.733 6.108
201708 4.284 245.519 5.762
201711 4.838 246.669 6.477
201802 4.327 248.991 5.738
201805 3.504 251.588 4.599
201808 5.452 252.146 7.140
201811 5.054 252.038 6.622
201902 4.439 252.776 5.799
201905 3.774 256.092 4.866
201908 3.396 256.558 4.371
201911 3.001 257.208 3.853
202002 2.121 258.678 2.708
202005 4.460 256.394 5.744
202008 4.227 259.918 5.370
202011 3.606 260.229 4.576
202102 5.319 263.014 6.678
202105 6.792 269.195 8.332
202108 9.984 273.567 12.051
202111 13.598 277.948 16.155
202203 12.813 287.504 14.716
202206 12.130 296.311 13.518
202209 11.969 296.808 13.316
202212 11.679 296.797 12.994
202303 11.496 301.836 12.577
202306 11.468 305.109 12.412
202309 11.268 307.789 12.089
202312 12.361 306.746 13.307
202403 12.517 312.332 13.234
202406 13.264 314.175 13.941
202409 11.842 315.301 12.402
202412 11.152 315.605 11.668
202503 10.492 319.799 10.834
202506 11.515 322.561 11.788
202509 15.150 324.800 15.402
202512 15.479 324.054 15.773
202603 17.720 330.213 17.720

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₪9.74 mean?
Oramed Pharmaceuticals (XTAE:ORMP) has a Cyclically Adjusted Book per Share of ₪9.74 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Oramed Pharmaceuticals' current Cyclically Adjusted Book per Share is ₪9.74. Overall, Oramed Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' Cyclically Adjusted Book per Share compare to CAMP and PYXS?
Oramed Pharmaceuticals' Cyclically Adjusted Book per Share of ₪9.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current Cyclically Adjusted Book per Share is ₪9.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (XTAE:ORMP) has a current Cyclically Adjusted Book per Share of ₪9.74. The current Cyclically Adjusted Book per Share is ₪9.74. Oramed Pharmaceuticals' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Oramed Pharmaceuticals (XTAE:ORMP), the current Cyclically Adjusted Book per Share is ₪9.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Other Exchanges ORMP:USAOJU1:Germany
Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
23GF Score

Get the complete analysis for XTAE:ORMP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪12.72
Price